Drug Database
Back to search

Japan· JP-2129011F2040

ベプリジル塩酸塩水和物

A bepridil product containing ベプリジル塩酸塩水和物, registered in Japan by トーアエイヨー, on the national reimbursement list.

On Japan’s NHI price listATC C08EA02

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedベプリジル塩酸塩水和物ATCC08EA02REGISTER NO.JP-2129011F2040PACKS LISTED0CHECKEDSeptember 25, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ベプリジル塩酸塩水和物Answers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

The record

At a glance

MHLW / PMDA (Japan)
Active substance
ベプリジル塩酸塩水和物
Manufacturer
トーアエイヨー
Country
Japan (JP)
ATC code
C08EA02
ATC class
Bepridil
Defined daily dose
0.3 g, O
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

277 interactions on record for bepridil.

Graded by severity as the source publishes them — 132 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check bepridil against other medicinesHow interaction checks work

Bepridil · interactions on record

277 records

  • 132 severe
  • 139 moderate
  • 6 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • OndansetronA04AA01severe
  • GranisetronA04AA02severe
  • DolasetronA04AA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under C08EA02

Bepridil, as other registers publish it.

All bepridil products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/de639e84-349d-4f2c-8694-c094d5449213
GET /v1/drugs/de639e84-349d-4f2c-8694-c094d5449213?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "１００ｍｇ１錠",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "2129011F2040",
  "category": "内用薬",
  "price_yen": 33.7,
  "generic_name": "ベプリジル塩酸塩水和物",
  "product_name_jp": null,
  "therapeutic_class": "2129",
  "transitional_expiry": null
}
API referenceMCP serverPlans

See everything about bepridil.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console